-
Mashup Score: 38
/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA)…
Source: www.prnewswire.comCategories: General Medicine News, Hem/OncsTweet
Supported by data from the Phase 3 MARIPOSA-2 study, #MyCompany submitted a sBLA to the U.S. FDA for the treatment of patients with locally advanced or metastatic EGFRm NSCLC after treatment with osimertinib. https://t.co/dzyUrMUFGc #MyCompany #Innovation #PrecisionMedicine https://t.co/x5aGsR8yRu